Antiviral Agents for Prevention of the Common Cold

Lowenstein SR , Parrino TA . Management of the common cold. Adv Intern Med 1987;32:207–234.

National Center for Health Statistics: Current estimates from the National Health Interview Survey, United States, 1982. Vital and Health Statistics Series 10, No. 150. U.S. Department of Health and Human Services, publication (PHS) 85-1578. Public Health Service, 1985.

Gold M , Azevedo D. The content of adult primary care episodes. Public Health Rep 1982;97:48–57.

Turner RB , Gwaltney JM . Symposium on rhinovirus pathogenesis. Acta Otolaryngol 1984;(Suppl 413):5–45.

Hendley JO . Rhinovirus colds: Immunology and pathogenesis. Eur J Respir Dis 1983;64(Suppl 128):340–343.

Gwaltney JM . Rhinovirus colds: Epidemiology, clinical character- istics and transmission. Eur J Respir Dis 1983;64(Suppl 128):336–339.

Anderson LJ , Patriarca PA , Hierholzer JC , Noble GR . Viral respiratory illnesses. Med Clin North Am 1983;67:1009–1030.

Rossmann MG , Arnold E , Erickson JW , . Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985;317:145–153.

Rossmann MG . The canyon hypothesis: Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem 1989;264:14587–14590.

Hayden FG , Douglas RG Jr . Antiviral agents. In: Mandell GL , Douglas RG Jr , Bennett JE , eds. Principles and practice of infectious diseases; 3rd ed. New York: Churchill Livingstone, 1990:359–380.

Phillpotts RJ , Wallace J , Tyrrell DAJ , Tagart VB . Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother 1983;23:671–675.

Tisdale M , Selway JWT . Effect of dichloroflavan (BW683c) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother 1984;14(Suppl A):97–105.

Phillpotts RJ , Wallace J , Tyrrell DAJ , Freestone D , Shepherd W. Failure of oral 4', 6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol 1983;75:115–121.

Ishitsuka H , Ninomiya YT , Ohsawa C , Fuju M. Direct and specific inactivation of rhinovirus by chalcone RO 09-0410. Antimicrob Agents Chemother 1982;22:617–621.

Zerial A , Werner GH , Phillpotts RJ , Willman JS , Higgins PG , Tyrrell DAJ . Studies on 44 081 RP, a new antirhinovirus compound in cell cultures and in volunteers. Antimicrob Agents Chemother 1985;27:846–850.

Smith TJ , Kremer MJ , Luo M , . The site of attachment in human rhinovirus-14 for antiviral agents that inhibit uncoating. Science 1986;223:1286–1293.

Tyrrell DAJ . Hot news on the common cold. Ann Rev Microbiol 1988;42:35–47.

Al-Nakib W , Tyrrell DAJ . A "new" generation of more potent synthetic antirhinovirus compounds: Comparison of their MICs and their synergistic interactions. Antiviral Res 1987;8:179–188.

Al-Nakib W , Higgins PG , Barrow GI , . Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R 61837). Antimicrob Agents Chemother 1989;33:522–525.

Whitaker-Dowling P , Youngner JS . Antiviral effects of interferon in different virus-host cell systems. In: Pfeffer LM , ed. Mechanisms of interferon actions; Vol 1. Boca Raton FL: CRC Press, 1987:83–98.

Douglas RB , Moore BW , Miles HB , . Prophylactic efficacy of intranasal alpha2 interferon against rhinovirus infections in the family setting. N Engl J Med 1986;314:65–70.

McKinlay MA , Rossmann MG . Rational design of antiviral agents. Annu Rev Pharmacol Toxicol 1989;29:111–122.

Crumpacker CS . Molecular targets of antiviral therapy. N Engl J Med 1989;321:163–172.